Abstract
Background
Recent publications have suggested considerable improvements in the clinical outcomes of ocular Behcet’s disease (BD) patients. However, the long-term time course of clinical ocular features of BD in recent cases remains largely unknown. In this study, we investigated annual time-course changes of best-corrected visual acuity (BCVA) during ocular convalescent stages, as well as annual frequency of ocular attacks during the initial 10 years of follow-up in patients with BD.
Methods
We studied 75 eyes in 39 patients (31 men, eight women) with BD, who were referred to our hospital between 1980 and 1996 within 1 year after the initial ocular attack and followed them up continuously for more than 10 years. The clinical courses of BCVA at the ocular convalescent stage from the onset of ocular disease were retrospectively examined, and the numbers of ocular attacks per eye per year were determined.
Results
Mean BCVA was 0.59 at 1 year, 0.31 at 3 years, and 0.12 at 10 years from the onset of ocular disease, while the numbers of ocular attacks per eye were 4.1 ± 3.1 at 1 year, 2.2 ± 1.9 at 5 years, and 1.4 ± 1.8 at 10 years. Ocular attacks were still observed in 33 eyes (45%) of 21 patients (54%) with BD even after 10 years. Final BCVA in 42 eyes (56%) became lower than 0.5. The major reasons for poor visual prognosis were macular atrophy (41%) and chorioretinal atrophy (26%).
Conclusions
The decline of BVCA continued, and nearly half the patients still suffered from ocular attacks at 10 years after the onset of ocular BD.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nakae K, Masaki F, Hashimoto F, Inaba G, Mochizuki M, Sakane T (1993) Recent epidemiological features of Behçet’s disease in Japan. In: Godeau P, Wechsler B (eds) Behçet’s disease. Excerpta Medica, Amsterdam, pp 145–151
Mochizuki M, Akduman L, Nussenblatt RB (1996) Behçet disease. In: Pepose JS, Holland GN, Wilhelmus KR (eds) Ocular infection and immunity. St. Louis, Mosby, pp 663–675
Evereklioglu C (2005) Current concepts in the etiology and treatment of Behçet disease. Surv Ophthalmol 50:297–350
Ohno S, Nakamura S, Hori S, Shimakawa M, Kawashima H, Mochizuki M, Sugita S, Ueno S, Yoshizaki K, Inaba G (2004) Efficacy, safety, and pharmacokinetics of multiple administration of infliximab in Behçet's disease with refractory uveoretinitis. J Rheumatol 31:1362–1368
Sfikakis PP, Theodossiadis PG, Katsiari CG, Kaklamanis P, Markomichelakis NN (2001) Effect of infliximab on sight-threatening panuveitis in Behçet's disease. Lancet 358:295–296
Niccoli L, Nannini C, Benucci M, Chindamo D, Cassarà E, Salvarani C, Cimino L, Gini G, Lenzetti I, Cantini F (2007) Long-term efficacy of infliximab in refractory posterior uveitis of Behçet's disease: a 24-month follow-up study. Rheumatology 46:1161–1164
Mishima S, Masuda K, Izawa Y, Mochizuki M, Namba K (1979) The eighth Frederick H. Verhoeff Lecture. Presented by Saiichi Mishima, MD. Behçet's disease in Japan: ophthalmologic aspects. Trans Am Ophthalmol Soc 77:225–79
Mamo JG (1970) The rate of visual loss in Behçet’s disease. Arch Ophthalmol 84:451–452
Benezra D, Cohen E (1986) Treatment and visual prognosis in Behçet's disease. Br J Ophthalmol 70:589–592
Mimura Y (1979) Immunopathological and clinical studies on ocular allergic diseases. J Jpn Ophthalmol Soc 83:1909–1975
Yuasa T (1991) The etiology and clinical statistics of Behçet’s disease. Ganka (Jpn J Clin Ophthalmol) 33:225–232
Miyake M, Sunagawa M, Okinami S (1997) Behçet’s disease characteristics more than 10 years after diagnosis. Folia Ophthalmol Jpn 48:707–712
Yoshida A, Kawashima H, Motoyama Y, Shibui H, Kaburaki T, Shimizu K, Ando K, Hijikata K, Izawa Y, Hayashi K, Numaga J, Fujino Y, Masuda K, Araie M (2004) Comparison of patients with Behçet's disease in the 1980s and 1990s. Ophthalmology 111:810–815
Takeuchi M, Hokama H, Tsukahara R, Kezuka T, Goto H, Sakai J, Usui M (2005) Risk and prognostic factors of poor visual outcome in Behçet's disease with ocular involvement. Graefe Arch Clin Exp Ophthalmol 243:1147–1152
Tugal-Tutkun I, Onal S, Altan-Yaycioglu R, Huseyin Altunbas H, Urgancioglu M (2004) Uveitis in Behçet disease: an analysis of 880 patients. Am J Ophthalmol 138:373–380
Kaçmaz RO, Kempen JH, Newcomb C, Gangaputra S, Daniel E, Levy-Clarke GA, Nussenblatt RB, Rosenbaum JT, Suhler EB, Thorne JE, Jabs DA, Foster CS, Systemic Immunosuppressive Therapy for Eye Diseases Cohort Study Group (2008) Ocular inflammation in Behçet disease: incidence of ocular complications and of loss of visual acuity. Am J Ophthalmol 146:828–836
Behçet’s Disease Research Committee of Japan (1997) The Revised Criteria and Manual of Treatments of Behçet’s disease. In: Report of Behçet Disease Research Comittee, Ministry of Health and Welfare of Japan, Tokyo, pp 22–29
Hogan MJ, Kimura SJ, Thygeson P (1959) Signs and symptoms of uveitis. I. Anterior uveitis. Am J Ophthalmol 47(5, Part 2):155–170
Demiroğlu H, Barişta I, Dündar S (1997) Risk factor assessment and prognosis of eye involvement in Behçet's disease in Turkey. Ophthalmology 104:701–705
Acknowledgements
Research supported in part by grants from Behçet Disease Research Comittee, Ministry of Health and Welfare, Tokyo, Japan.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kaburaki, T., Araki, F., Takamoto, M. et al. Best-corrected visual acuity and frequency of ocular attacks during the initial 10 years in patients with Behçet’s disease. Graefes Arch Clin Exp Ophthalmol 248, 709–714 (2010). https://doi.org/10.1007/s00417-009-1234-z
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00417-009-1234-z